Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-based early warning system for hemorrhage risk from cefoperazone + sulbactam in preterm neonates
ChiCTR2200057588Phase 4Not yet recruiting
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- Mar 2022
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cefoperazone + sulbactam in Infectious disease (2 arms), sponsored by Affiliated Suzhou Hospital of Nanjing Medical University. Primary endpoints: Trough plasma concentration of cefoperazone + sulbactam, Blood routine and 3 more. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
cefoperazone + sulbactam
03
Conditions
Infectious disease
Beyond the preview
Go deeper on ChiCTR2200057588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057588.